|
1
|
Monson K, Litvak DA and Bold RJ: Surgery
in the aged population: Surgical oncology. Arch Surg.
138:1061–1067. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Platz CE and Benda JA: Female genital
tract cancer. Cancer. 75:270–294. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Randall ME, Filiaci VL, Muss H, Spirtos
NM, Mannel RS, Fowler J, Thigpen JT and Benda JA: Gynecologic
Oncology Group Study: Randomized phase III trial of whole-abdominal
irradiation versus doxorubicin and cisplatin chemotherapy in
advanced endometrial carcinoma: A Gynecologic Oncology Group study.
J Clin Oncol. 24:36–44. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fleming GF, Brunetto VL, Cella D, Look KY,
Reid GC, Munkarah AR, Kline R, Burger RA, Goodman A and Burks RT:
Phase III trial of doxorubicin plus cisplatin with or without
paclitaxel plus filgrastim in advanced endometrial carcinoma: A
gynecologic oncology group study. J Clin Oncol. 22:2159–2166. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Miller D, Fillaci V, Fleming G, Mannel R,
Cohn D, Matsumoto T, Tewari K, DiSilvestro P, Pearl M and Zaino R:
Randomized phase III noninferiority trial of first-line
chemotherapy for metastatic or recurrent endometrial carcinoma: A
Gynecologic Oncology Group study. Gynecol Oncol. 125:771–773. 2012.
View Article : Google Scholar
|
|
7
|
Nomura H, Aoki D, Takahashi F, Katsumata
N, Watanabe Y, Konishi I, Jobo T, Hatae M, Hiura M and Yaegashi N:
Randomized phase II study comparing docetaxel plus cisplatin,
docetaxel plus carboplatin, and paclitaxel plus carboplatin in
patients with advanced or recurrent endometrial carcinoma: A
Japanese Gynecologic Oncology Group study (JGOG2041). Ann Oncol.
22:636–642. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
ScribnerDR Jr, Puls LE and Gold MA: A
phase II evaluation of docetaxel and carboplatin followed by tumor
volume directed pelvic plus or minus paraaortic irradiation for
stage III endometrial cancer. Gynecol Oncol. 125:388–393. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Geller MA, Ivy JJ, Ghebre R, Downs LS Jr,
Judson PL, Carson LF, Jonson AL, Dusenbery K, Vogel RI, Boente MP,
et al: A phase II trial of carboplatin and docetaxel followed by
radiotherapy given in a ‘sandwich’ method for stage III, IV and
recurrent endometrial cancer. Gynecol Oncol. 121:112–117. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yoshimura N, Kudoh S, Kimura T, Mitsuoka
S, Kyoh S, Tochino Y, Asai K, Kodama T, Ichimaru Y, Yana T and
Hirata K: Phase II study of docetaxel and carboplatin in elderly
patients with advanced non-small cell lung cancer. J Thorac Oncol.
4:371–375. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim HJ, Kim TG, Lee HJ, Kim JH, Lim BH,
Seo JW, Kang EM, Lee BU, Ahn YM, Roh YH, et al: A phase II study of
combination chemotherapy with docetaxel and carboplatin for elderly
patients with advanced non-small cell lung cancer. Lung Cancer.
68:248–252. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kurt E, Cubukcu E, Karabulut B, Olmez OF,
Kurt M, Avci N, Ozdemir F, Tunali D, Evrensel T and Manavoglu O: A
multi-institutional evaluation of carboplatin plus docetaxel
regimen in elderly patients with advanced gastric cancer. J BUON.
18:147–153. 2013.PubMed/NCBI
|
|
13
|
Pecorelli S: Revised FIGO staging for
carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol
Obstet. 105:103–104. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cockcroft DW and Gault MH: Prediction of
clearance from serum creatinine. Nephron. 16:31–41. 1976.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
National Cancer Institute: Common
Terminology Criteria for Adverse Events (CTCAE) version 4.0.
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40Accessed.
June 21–2015
|
|
16
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van
Oosterom AT, Christian MC and Gwyther SG: New guidelines to
evaluate the response to treatment in solid tumors. European
Organization for Research and Treatment of Cancer, National Cancer
Institute of the United States, National Cancer Institute of
Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Goldberg RM, Tabah-Fisch I, Bleiberg H, de
Gramont A, Tournigand C, Andre T, Rothenberg ML, Green E and
Sargent DJ: Pooled analysis of safety and efficacy of oxaliplatin
plus fluorouracil/leucovorin administered bimonthly in elderly
patients with colorectal cancer. J Clin Oncol. 24:4085–4091. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kabbinavar FF, Schulz J, McCleod M, Patel
T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B and Novotny WF:
Addition of bevacizumab to bolus fluorouracil and leucovorin in
first-line metastatic colorectal cancer: Results of a randomized
phase II trial. J Clin Oncol. 23:3697–3705. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pinder MC, Duan Z, Goodwin JS, Hortobagyi
GN and Giordano SH: Congestive heart failure in older women treated
with adjuvant anthracycline chemotherapy for breast cancer. J Clin
Oncol. 25:3808–3815. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Muss HB, Woolf S, Berry D, Cirrincione C,
Weiss RB, Budman D, Wood WC, Henderson IC, Hudis C, Winer E, et al:
Adjuvant chemotherapy in older and younger women with lymph
node-positive breast cancer. JAMA. 293:1073–1081. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fairfield KM, Murray K, Lucas FL, Wierman
HR, Earle CC, Trimble EL, Small L and Warren JL: Completion of
adjuvant chemotherapy and use of health services for older women
with epithelial ovarian cancer. J Clin Oncol. 29:3921–3926. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sundararajan V, Hershman D, Grann VR,
Jacobson JS and Neugut AI: Variations in the use of chemotherapy
for elderly patients with advanced ovarian cancer: A
population-based study. J Clin Oncol. 20:173–178. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Eisenhauer EL, Tew WP, Levine DA, Lichtman
SM, Brown CL, Aghajanian C, Huh J, Barakat RR and Chi DS: Response
and outcomes in elderly patients with stages IIIC-IV ovarian cancer
receiving platinum-taxane chemotherapy. Gynecol Oncol. 106:381–387.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
ten Tije AJ, Verweij J, Carducci MA,
Graveland W, Rogers T, Pronk T, Verbruggen MP, Dawkins F and Baker
SD: Prospective evaluation of the pharmacokinetics and toxicity
profile of docetaxel in the elderly. J Clin Oncol. 23:1070–1077.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Italiano A, Ortholan C, Oudard S, Pouessel
D, Gravis G, Beuzeboc P, Bompas E, Fléchon A, Joly F, Ferrero JM
and Fizazi K: Docetaxel-based chemotherapy in elderly patients (age
75 and older) with castration-resistant prostate cancer. Eur Urol.
55:1368–1375. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Belani CP and Fossella F: Elderly subgroup
analysis of a randomized phase III study of docetaxel plus platinum
combinations versus vinorelbine plus cisplatin for first-line
treatment of advanced nonsmall cell lung carcinoma (TAX 326).
Cancer. 104:2766–2774. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fader AN, von Gruenigen V, Gibbons H,
Abushahin F, Starks D, Markman M, Belinson J and Rose P: Improved
tolerance of primary chemotherapy with reduced-dose carboplatin and
paclitaxel in elderly ovarian cancer patients. Gynecol Oncol.
109:33–38. 2008. View Article : Google Scholar : PubMed/NCBI
|
